focus -WSS

focus

author：focus 2025-09-30 21:57:08 - browse：76

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： What’s missing from the debate over nursing home staff minimums

WSS

Readout LOUD: Venture capital, Gilead, and more M&A

Insmed lung disease drug hits target in key Phase 3 trial

Addiction doctors spar with methadone clinics over legislation

Addiction doctors spar with methadone clinics over legislation

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Heat waves linked to early deliveries, preterm births in new study

Wikipedia

focus

entertainment

In Memoriam: Notable people who died in 2023

Why Novartis is going to walk from its acquisition of MorphoSys

Affirmative action in medical school literally saved lives

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

iTeos Therapeutics debuts first data on TIGIT

What does generative AI mean for health care? We asked experts

Global cancer cases to surge 77% by 2050, WHO report says

Activists slam private health insurers over coverage restrictions

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

focus

The Biogen Aduhelm mess could happen again

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

iTeos Therapeutics debuts first data on TIGIT

Adam's Biotech Scorecard: Do Sarepta's exon

Top private equity targets in 2023: cardiology, clinical trials, lasers

Readout LOUD: Venture capital, Gilead, and more M&A

Wikipedia

hotspot

focus

hotspot